- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Jasper Therapeutics Inc (JSPR)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: JSPR (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $18.14
1 Year Target Price $18.14
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.2% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 47.85M USD | Price to earnings Ratio - | 1Y Target Price 18.14 |
Price to earnings Ratio - | 1Y Target Price 18.14 | ||
Volume (30-day avg) 11 | Beta 3.06 | 52 Weeks Range 1.39 - 23.37 | Updated Date 12/6/2025 |
52 Weeks Range 1.39 - 23.37 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.82 |
Earnings Date
Report Date 2025-11-10 | When - | Estimate -2 | Actual -1.13 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -72.92% | Return on Equity (TTM) -191.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3022336 | Price to Sales(TTM) - |
Enterprise Value -3022336 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.42 | Shares Outstanding 27984039 | Shares Floating 21701342 |
Shares Outstanding 27984039 | Shares Floating 21701342 | ||
Percent Insiders 1.04 | Percent Institutions 74.06 |
Upturn AI SWOT
Jasper Therapeutics Inc

Company Overview
History and Background
Jasper Therapeutics Inc. was founded in 2011 (initially as Abzena plc, then spun out and rebranded). It's a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics for autoimmune diseases and cancer. A significant milestone was its IPO in August 2020. The company has evolved by focusing its pipeline on specific targets within the immunology and oncology space.
Core Business Areas
- Therapeutic Development: Jasper Therapeutics Inc. is primarily engaged in the discovery, development, and commercialization of antibody-based therapeutics. Their pipeline targets unmet medical needs in both autoimmune diseases and oncology.
Leadership and Structure
Jasper Therapeutics Inc. is led by a management team with extensive experience in biotechnology and pharmaceutical development. The specific organizational structure is typical of a clinical-stage biotech, with dedicated departments for research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- JTX-801: A novel antibody designed to target the JAK-STAT signaling pathway, with potential applications in autoimmune diseases and hematologic malignancies. Market share data is not applicable at this clinical stage. Key competitors in the JAK inhibitor space include companies like Pfizer (Xeljanz), AbbVie (Rinvoq), and Eli Lilly (Olumiant).
- JTX-201: An investigational antibody targeting CD47, a 'don't eat me' signal that cancer cells use to evade the immune system. This is being developed for various solid tumors and hematologic malignancies. Market share data is not applicable at this clinical stage. Key competitors in the CD47 inhibitor space include companies like Gilead Sciences (magrolimab), Trillium Therapeutics (acquired by Pfizer), and Forty Seven Inc. (acquired by Gilead).
Market Dynamics
Industry Overview
The biotechnology and pharmaceutical industry is characterized by intense research and development, long product development cycles, high regulatory hurdles, and significant market potential for successful therapeutics, especially in oncology and autoimmune diseases. The market for autoimmune disease treatments is substantial and growing, driven by increasing prevalence and demand for more effective therapies. The oncology market, particularly for immunotherapies, is also experiencing rapid growth and innovation.
Positioning
Jasper Therapeutics Inc. is positioned as a clinical-stage biotechnology company focused on developing innovative antibody-based therapies. Its competitive advantage lies in its targeted approach to specific disease pathways and its potential to develop first-in-class or best-in-class treatments. However, as a clinical-stage company, it faces significant risk and has no established market share.
Total Addressable Market (TAM)
The TAM for autoimmune diseases and oncology is in the hundreds of billions of dollars globally. Jasper Therapeutics Inc. is targeting specific segments within these broad markets. Their positioning relative to the TAM is that of a developing player with the potential to capture a niche within these large markets if their pipeline candidates prove successful in late-stage trials and gain regulatory approval.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on novel antibody-based therapeutics
- Pipeline targets significant unmet medical needs
- Potential for first-in-class or best-in-class therapies
Weaknesses
- Clinical-stage company with no approved products
- Reliance on future clinical trial success
- Significant cash burn required for R&D
- Limited historical financial performance data due to early stage
Opportunities
- Growing demand for innovative treatments in autoimmune diseases and cancer
- Potential for strategic partnerships or acquisitions
- Advancements in antibody engineering and immunotherapy
- Expansion into new therapeutic indications
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Intense competition from established and emerging biotech companies
- Patent challenges and intellectual property disputes
- Funding risks and market volatility
Competitors and Market Share
Key Competitors
- Gilead Sciences (GILD)
- AbbVie Inc. (ABBV)
- Pfizer Inc. (PFE)
- Eli Lilly and Company (LLY)
- Imago BioSciences Inc. (IMGO) (Acquired by Eli Lilly)
Competitive Landscape
Jasper Therapeutics Inc. operates in highly competitive therapeutic areas with numerous established pharmaceutical companies and emerging biotechnology firms. Its advantage lies in its specific molecular targets and potential for novel mechanisms of action. However, it faces significant challenges in competing with companies that have established market presence, extensive commercial infrastructure, and diversified pipelines.
Growth Trajectory and Initiatives
Historical Growth: Jasper Therapeutics Inc.'s historical growth has been primarily in terms of pipeline advancement, scientific milestones, and securing funding through equity offerings. Revenue growth is not a primary metric at this stage.
Future Projections: Future projections for Jasper Therapeutics Inc. are highly speculative and depend heavily on the success of its ongoing clinical trials. Analyst estimates, if available, would focus on potential peak sales if products are approved, and the probability-adjusted value of its pipeline. Without specific analyst reports, general projections are difficult to provide.
Recent Initiatives: Recent initiatives likely involve advancing its lead drug candidates through clinical trials, exploring potential collaborations, and potentially seeking additional funding rounds to support ongoing development.
Summary
Jasper Therapeutics Inc. is a promising clinical-stage biotechnology company with a focused pipeline targeting significant unmet needs in autoimmune diseases and cancer. Its strengths lie in its novel antibody-based approach and experienced team. However, it faces substantial risks associated with clinical trial failures, regulatory approvals, and intense competition. Continued successful progression of its pipeline and securing adequate funding are critical for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Jasper Therapeutics Inc. SEC Filings (e.g., 10-K, 10-Q)
- Financial news outlets (e.g., Bloomberg, Reuters)
- Biotechnology industry analysis reports
- Company investor relations materials
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jasper Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2021-09-24 | President, CEO & Director Mr. Ronald A. Martell | ||
Sector Healthcare | Industry Biotechnology | Full time employees 27 | Website https://jaspertx.com |
Full time employees 27 | Website https://jaspertx.com | ||
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

